Laurus Labs Ltd.

NSE: LAURUSLABS | BSE: 540222 | ISIN: INE947Q01028 | Industry: Pharmaceuticals
| Expensive Performer
603.0500 -0.65 (-0.11%)
NSE May 16, 2025 15:31 PM
Volume: 1.5M
 

logo
Laurus Labs Ltd.
30 Apr 2021
603.05
-0.11%
ICICI Securities Limited
Laurus is well poised to follow the success story of some leading CDMO players backed by strong chemistry and integrated model. Elsewhere, formulations are expected to grow amid ramp up and new launches (e.g. TLE400) in LMIC and launches in the US. Other APIs are expected to be driven by a strong order book and capacity addition. Besides continuous improvement in the financial performances, the company is evolving as a strong vertically integrated player with strong order book visibility, improving margin profile, strengthening return ratios and healthy FCF...
Number of FII/FPI investors increased from 237 to 259 in Mar 2025 qtr.
More from Laurus Labs Ltd.
Recommended